Literature DB >> 29464466

WhichP450: a multi-class categorical model to predict the major metabolising CYP450 isoform for a compound.

Peter A Hunt1, Matthew D Segall2, Jonathan D Tyzack3.   

Abstract

In the development of novel pharmaceuticals, the knowledge of how many, and which, Cytochrome P450 isoforms are involved in the phase I metabolism of a compound is important. Potential problems can arise if a compound is metabolised predominantly by a single isoform in terms of drug-drug interactions or genetic polymorphisms that would lead to variations in exposure in the general population. Combined with models of regioselectivities of metabolism by each isoform, such a model would also aid in the prediction of the metabolites likely to be formed by P450-mediated metabolism. We describe the generation of a multi-class random forest model to predict which, out of a list of the seven leading Cytochrome P450 isoforms, would be the major metabolising isoforms for a novel compound. The model has a 76% success rate with a top-1 criterion and an 88% success rate for a top-2 criterion and shows significant enrichment over randomised models.

Entities:  

Keywords:  Cytochrome P450; Drug–drug interactions; Metabolism; Multi-class classification; Random forests

Mesh:

Substances:

Year:  2018        PMID: 29464466     DOI: 10.1007/s10822-018-0107-0

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  11 in total

1.  WhichCyp: prediction of cytochromes P450 inhibition.

Authors:  Michal Rostkowski; Ola Spjuth; Patrik Rydberg
Journal:  Bioinformatics       Date:  2013-06-05       Impact factor: 6.937

Review 2.  Update on the pharmacogenomics of proton pump inhibitors.

Authors:  Krisztina Hagymási; Katalin Müllner; László Herszényi; Zsolt Tulassay
Journal:  Pharmacogenomics       Date:  2011-06       Impact factor: 2.533

Review 3.  Predicting drug metabolism: experiment and/or computation?

Authors:  Johannes Kirchmair; Andreas H Göller; Dieter Lang; Jens Kunze; Bernard Testa; Ian D Wilson; Robert C Glen; Gisbert Schneider
Journal:  Nat Rev Drug Discov       Date:  2015-04-24       Impact factor: 84.694

4.  O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants.

Authors:  S M Fogelman; J Schmider; K Venkatakrishnan; L L von Moltke; J S Harmatz; R I Shader; D J Greenblatt
Journal:  Neuropsychopharmacology       Date:  1999-05       Impact factor: 7.853

5.  Predicting Regioselectivity and Lability of Cytochrome P450 Metabolism Using Quantum Mechanical Simulations.

Authors:  Jonathan D Tyzack; Peter A Hunt; Matthew D Segall
Journal:  J Chem Inf Model       Date:  2016-10-26       Impact factor: 4.956

6.  Prediction of cytochrome P450 isoform responsible for metabolizing a drug molecule.

Authors:  Nitish K Mishra; Sandhya Agarwal; Gajendra Ps Raghava
Journal:  BMC Pharmacol       Date:  2010-07-16

Review 7.  Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation.

Authors:  Ulrich M Zanger; Matthias Schwab
Journal:  Pharmacol Ther       Date:  2013-01-16       Impact factor: 12.310

Review 8.  Synthetic and natural compounds that interact with human cytochrome P450 1A2 and implications in drug development.

Authors:  Bo Wang; Shu-Feng Zhou
Journal:  Curr Med Chem       Date:  2009       Impact factor: 4.530

9.  Integration of pharmacometabolomics with pharmacokinetics and pharmacodynamics: towards personalized drug therapy.

Authors:  Vasudev Kantae; Elke H J Krekels; Michiel J Van Esdonk; Peter Lindenburg; Amy C Harms; Catherijne A J Knibbe; Piet H Van der Graaf; Thomas Hankemeier
Journal:  Metabolomics       Date:  2016-12-19       Impact factor: 4.290

Review 10.  The Role of CYP2E1 in the Drug Metabolism or Bioactivation in the Brain.

Authors:  W A García-Suástegui; L A Ramos-Chávez; M Rubio-Osornio; M Calvillo-Velasco; J A Atzin-Méndez; J Guevara; D Silva-Adaya
Journal:  Oxid Med Cell Longev       Date:  2017-01-10       Impact factor: 6.543

View more
  8 in total

Review 1.  Advances in the study of drug metabolism - symposium report of the 12th Meeting of the International Society for the Study of Xenobiotics (ISSX).

Authors:  Laura E Russell; Mary Alexandra Schleiff; Eric Gonzalez; Aaron G Bart; Fabio Broccatelli; Jessica H Hartman; W Griffith Humphreys; Volker M Lauschke; Iain Martin; Chukwunonso Nwabufo; Bhagwat Prasad; Emily E Scott; Matthew Segall; Ryan Takahashi; Mitchell E Taub; Jasleen K Sodhi
Journal:  Drug Metab Rev       Date:  2020-05-26       Impact factor: 4.518

2.  LC-MS/MS Estimation of Rociletinib Levels in Human Liver Microsomes: Application to Metabolic Stability Estimation.

Authors:  Mohamed W Attwa; Ali S Abdelhameed; Adnan A Kadi
Journal:  Drug Des Devel Ther       Date:  2021-09-15       Impact factor: 4.162

3.  Rapid Optimization of the Metabolic Stability of a Human Immunodeficiency Virus Type-1 Capsid Inhibitor Using a Multistep Computational Workflow.

Authors:  Megan E Meuser; Poli Adi Narayana Reddy; Alexej Dick; Jean Marc Maurancy; Joseph M Salvino; Simon Cocklin
Journal:  J Med Chem       Date:  2021-03-22       Impact factor: 7.446

Review 4.  Computational methods and tools to predict cytochrome P450 metabolism for drug discovery.

Authors:  Jonathan D Tyzack; Johannes Kirchmair
Journal:  Chem Biol Drug Des       Date:  2019-01-15       Impact factor: 2.817

Review 5.  Artificial Intelligence in Drug Discovery: A Comprehensive Review of Data-driven and Machine Learning Approaches.

Authors:  Hyunho Kim; Eunyoung Kim; Ingoo Lee; Bongsung Bae; Minsu Park; Hojung Nam
Journal:  Biotechnol Bioprocess Eng       Date:  2021-01-07       Impact factor: 3.386

6.  A validated LC-MS/MS analytical method for the quantification of pemigatinib: metabolic stability evaluation in human liver microsomes.

Authors:  Mohamed W Attwa; Ali S Abdelhameed; Nawaf A Alsaif; Adnan A Kadi; Haitham AlRabiah
Journal:  RSC Adv       Date:  2022-07-13       Impact factor: 4.036

7.  Profiling of in vivo, in vitro and reactive zorifertinib metabolites using liquid chromatography ion trap mass spectrometry.

Authors:  Nasser S Al-Shakliah; Adnan A Kadi; Haya I Aljohar; Haitham AlRabiah; Mohamed W Attwa
Journal:  RSC Adv       Date:  2022-07-21       Impact factor: 4.036

8.  Composition and Orientation of the Core Region of Novel HIV-1 Entry Inhibitors Influences Metabolic Stability.

Authors:  Rama Karadsheh; Megan E Meuser; Simon Cocklin
Journal:  Molecules       Date:  2020-03-21       Impact factor: 4.411

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.